Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Page Options
E-Mail This Search
Clinical Trial Questions?
Get Help:
1-800-4-CANCER
or
LiveHelp online chat
Quick Links
Help Using the NCI Clinical Trials Search Form
Educational Materials About Clinical Trials
About NCI's Cancer Clinical Trials Registry
Dictionary of Cancer Terms
NCI Drug Dictionary
View Content for:
Patients
Health Professionals
Display:
Title
Description with:
Locations
Eligibility
Full Trial Description
Custom
Results 1-25 of 41 for your search:
Cancer Type:
Lymphoma, non-Hodgkin lymphoma, child
Stage/Subtype of Cancer:
stage IV childhood large cell lymphoma
Country:
U.S.A.
Trial Type:
Treatment
Trial Status:
Active
Hide Search Criteria
Show Search Criteria
Help with Results
Select All on Page
Sort by:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Show
10
25
50
100
200
Results per Page
1.
Phase III Randomized Study of Glutamic Acid in Reducing Vincristine-Related Peripheral Neurotoxicity in Young Patients Undergoing Vincristine-Containing Treatment for Wilms' Tumor, Rhabdomyosarcoma, Acute Lymphoblastic Leukemia, or Non-Hodgkin's Lymphoma
Phase:
Phase III
Type:
Supportive care, Treatment
Status:
Active
Age:
3 to 20
Sponsor:
NCI
Protocol IDs:
HLMCC-0402
, NCT00369564, ACCL 0731
2.
Phase I/II Study of Epstein Barr Virus Specific Cytotoxic T Lymphocytes from a Normal HLA-Compatible Donor in the Treatment of Patients With Epstein Barr Virus Associated Lymphomas and Other Lymphoproliferative Diseases
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
Not specified
Sponsor:
Other
Protocol IDs:
MSKCC-95024
, NCI-V95-0685, NCT00002663
3.
Phase I/II Study of Reduced-Intensity Preparative Regimen Comprising Fludarabine, Busulfan, and Alemtuzumab Followed By Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematological Malignancies or Other Diseases
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
70 and under
Sponsor:
Other
Protocol IDs:
BCM-H-19386
, BCM-FAB, H 19386, NCT00625144
4.
Phase I/II Pilot Study of WT-1 Peptide-Loaded Allogeneic Dendritic Cell Vaccine and Donor Lymphocyte Infusion in Patients With WT1-Expressing Progressive or Relapsed Hematologic Malignancies After Prior Allogeneic Stem Cell Transplantation
Phase:
Phase II, Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
1 to 75
Sponsor:
NCI
Protocol IDs:
NCI-08-C-0051
, 08-C-0051, NCI-P06049, NCT00608166
5.
Unrelated Cord Blood Transplant Plus a Haplo-Identical (Half-Matched), T-Cell Depleted Stem Transplant From a Related Donor for Subjects With High Risk Malignancies
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
0 to 55
Sponsor:
Other
Protocol IDs:
8717
, NCT00673114
6.
A Multi-Center Phase I Study of AP23573 in Pediatric Patients With Advanced Solid Tumors
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
1 to 17
Sponsor:
Other
Protocol IDs:
SUN08-01
, NCT00704054
7.
Phase I/II Study of Dasatinib in Combination With Ifosfamide, Carboplatin, and Etoposide Phosphate in Young Patients With Metastatic or Recurrent Malignant Solid Tumors
Phase:
Phase II, Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
1 to 25
Sponsor:
NCI, Pharmaceutical / Industry
Protocol IDs:
CHNMC-07053
, 07053, CA180 121, NCT00788125
8.
Phase II Study of Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematologic Malignancy
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
65 and under
Sponsor:
NCI
Protocol IDs:
CPMC-IRB-AAAA5571
, CPMC-CAMP-016, NCI-G00-1891, NCT00008216
9.
Phase II Study of Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (EPOCH) With Rituximab and Filgrastim (G-CSF) in Patients With Stage I-IV Non-Hodgkin's Lymphoma
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
18 and over for Burkitt's lymphoma
Sponsor:
NCI
Protocol IDs:
NCI-93-C-0133
, CRB-9307, NCI-MB-303, NCI-T93-0023N, T93-0023, NCT00018980
10.
Phase II Study of Umbilical Cord Blood as a Source of Hematopoietic Stem Cells for Transplantation in Children With Malignant or Non-Malignant Diseases
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
21 and under
Sponsor:
Other
Protocol IDs:
PSCI-2003-232
, NCT00084695
11.
Phase II Study of a Myeloablative Preparative Regimen Comprising Busulfan, Melphalan, and Thiotepa Followed By Autologous Peripheral Blood Stem Cell Transplantation in Patients With Hodgkin's or Non-Hodgkin's Lymphoma
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
70 years and younger
Sponsor:
NCI
Protocol IDs:
OHSU-HEM-04083-L
, OHSU-IRB-248, NCT00238433
12.
Phase II Study of Myeloablative Preparative Regimen Comprising Fludarabine, Cyclophosphamide, and Total-Body Irradiation in Patients Undergoing Unrelated Umbilical Cord Blood Transplantation for Hematologic Malignancies
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
45 and under
Sponsor:
NCI
Protocol IDs:
UMN-2005LS043
, UMN-BMT-MT2005-10, UMN-MT2005-10, UMN-0507M71475, NCT00309842
13.
Phase II Study of Nonmyeloablative Conditioning Regimen Comprising Fludarabine, Cyclophosphamide, and Total-Body Irradiation Followed by Umbilical Cord Blood Transplantation and Post-Transplant Immunosuppression Comprising Cyclosporine and Mycophenolate Mofetil in Patients With Hematologic Malignancies
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
Under 70
Sponsor:
NCI
Protocol IDs:
UMN-2005LS036
, UMN-MT-2005-02, UMN-0507M70121, NCT00305682
14.
Phase II Study of Autologous Peripheral Blood Stem Cell Transplantation in Patients With Non-Hodgkin's or Hodgkin's Lymphoma
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
Under 70
Sponsor:
NCI
Protocol IDs:
UMN-2005LS048
, UMN-0508M72589, UMN-MT2004-24, NCT00345865
15.
Phase II Pilot Study of Etoposide, Cyclophosphamide, Thalidomide, Celecoxib, and Fenofibrate in Young Patients With Relapsed or Progressive Cancer
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
21 and under
Sponsor:
Other
Protocol IDs:
DFCI-04343
, 04-343, NCT00357500
16.
Rituximab-HCVAD in Patients With B-Cell Non-Hodgkin's Lymphoma
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
16 to 60
Sponsor:
Other
Protocol IDs:
2005-0054
, NCT00290498
17.
Phase II Study of Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematologic Cancer or Other Diseases
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
70 years old and under
Sponsor:
NCI
Protocol IDs:
CCCWFU-29506
, CCCWFU 29506, NCT00453206, CCCWFU-IRB00001366
18.
Phase II Pilot Study of Irradiated Allogeneic Related Donor Lymphocyte Infusion in Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor
Phase:
Phase II
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
Any age
Sponsor:
NCI
Protocol IDs:
CINJ-3330
, NCT00161187
19.
Phase II Study of Unrelated Umbilical Cord Blood Transplantation in Combination With a Myeloablative Preparative Regimen Comprising Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Patients With Hematological Diseases
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
6 months to 45 years
Sponsor:
NCI
Protocol IDs:
FHCRC-2010.00
, 6095, NCT00719888
20.
Phase II Study of Unrelated Donor Umbilical Cord Blood Transplantation Using a Reduced-Intensity Preparative Regimen in Patients With Hematological Malignancies
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
Any age
Sponsor:
NCI
Protocol IDs:
FHCRC-2239.00
, 6722, FHCRC-IR-6722, NCT00723099
21.
Phase II Study of Early Administration of Low-Dose Anti-Thymocyte Globulin followed by Low-Dose Cyclophosphamide, Busulfan, and Fludarabine to Optimize Outcome of Reduced-Intensity Conditioning for Allogeneic Peripheral Blood Progenitor Cell Transplantation From a Matched Related Donor in Patients With Lymphomas, Hodgkins Disease, Leukemias, Myelodysplastic Syndrome or Renal Cell Cancer
Phase:
Phase II
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
75 and under
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
BMTGG-NSH-807
, NSH 807, NCT00787761
22.
Evaluating the Safety and Effectiveness of an Umbilical Cord Blood Stem Cell Transplant That Uses Low Dose Chemotherapy in People With Leukemia or Lymphoma (BMT CTN #0604)
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
1 to 70
Sponsor:
NCI, NHLBI
Protocol IDs:
606
, U01 HL069294, NCT00864227
23.
Phase I Pilot Study of Myeloablative Conditioning Comprising Fludarabine, Cyclophosphamide, and Total-Body Irradiation Followed By Ex Vivo-Expanded Umbilical Cord Blood Progenitors and Unmanipulated Umbilical Cord Blood Transplantation and Immunosuppression Comprising Cyclosporine and Mycophenolate Mofetil in Patients With Hematologic Cancer and Other Diseases
Phase:
Phase I
Type:
Treatment
Status:
Active
Age:
6 months to 45 years
Sponsor:
NCI, Pharmaceutical / Industry
Protocol IDs:
FHCRC-2044.00
, AMGEN-200981, NCT00343798
24.
Phase I Study of Lexatumumab With or Without Recombinant Interferon Gamma in Pediatric Patients With Relapsed or Refractory Solid Tumors or Lymphoma
Phase:
Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
1 to 21
Sponsor:
NCI
Protocol IDs:
NCI-07-C-0040
, NCI-P6981, NCT00428272
25.
Topotecan, Ifosfamide and Carboplatin in Children and Young Adults With Solid Tumors
Phase:
Phase I
Type:
Treatment
Status:
Active
Age:
45 and under
Sponsor:
Other
Protocol IDs:
2004-0079
, NCT00502892
Select All on Page
1
Help with Results
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute
